![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 28, 25457-25464, July 12, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
From the
Institut de Pharmacologie Moléculaire
et Cellulaire, Unité Mixte de Recherche 6097, Centre National de
la Recherche Scientifique, 660 Route des Lucioles, 06560 Valbonne,
France, the § Institut de Génétique Humaine,
Centre National de la Recherche Scientifique, 34396 Montpellier,
France, and the ¶ Service de Pharmacologie et d'Immunologie,
Commisariat à l'Energie Atomique,
91191 Gif-sur-Yvette, cedex, France
Received for publication, April 5, 2002, and in revised form, April 24, 2002
| |
ABSTRACT |
|---|
|
|
|---|
Conversion of the normal membrane-bound prion
protein (PrP-sen) to its pathological isoform (PrP-res) is a key event
in the pathogenesis of transmissible spongiform encephalopathies.
Although the subcellular sites of conversion are poorly characterized, several lines of evidence have suggested the involvement of membrane lipid rafts in the conversion process. Here we report that copper stimulates the endocytosis of PrP-sen via a
caveolin-dependent pathway in both microglia and
neuroblastoma cells. We show that the polyene antibiotic filipin both
limits endocytosis of PrP-sen and dramatically reduces the amount of
membrane-bound PrP-sen. This reduction results from a rapid and massive
release of full matured PrP-sen into the culture medium. Finally, we
demonstrate that filipin is a potent inhibitor of PrP-res formation
into chronically infected neuroblastoma cells. Our results reinforce
the role of rafts in PrP trafficking and raise the possibility that the
release of PrP-sen from the plasma membrane decreases the amount of
available substrate PrP-sen at the conversion sites.
Transmissible spongiform encephalopathies
(TSE)1 are infectious
neurodegenerative diseases including scrapie of sheep, bovine encephalopathy in cattle, and a variety of human diseases such as
Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheincher syndrome, and fatal familial insomnia. TSE are associated with the
conversion of the protease-sensitive normal isoform of the prion
protein (PrP-sen) to a pathological scrapie isoform named PrPsc or
PrP-res based on its protease resistance. No differences in
distribution charges and amino-terminal sequences have been detected
between the isoforms (1); however, PrP-sen and PrP-res conformations
differ markedly (2). PrP-sen is a protease-sensitive monomeric protein,
whereas PrP-res forms highly insoluble aggregates characterized by
their resistance to proteolytic digestion (3). The conversion may occur
via a post-translational process without any chemical modifications of
the molecules (4, 5). Direct interactions between PrP-sen and PrP-res
aggregates and the conversion process resulting from it are molecular
key events in the development of TSE pathogenesis.
PrP-sen is bound to the external surface of the plasma membrane by a
glycosylphosphatidylinositol (GPI) anchor. Like most GPI-anchored
proteins, PrP-sen is clustered into cholesterol- and sphingomyelin-rich
domains called rafts or caveolae-rich domains, referring to the
presence of the protein marker caveolin (6, 7). However, it has been
shown that cells poorly expressing caveolin such as neuroblastoma cells
(N2a) also contain rafts based on the existence of detergent-resistant
membranes enriched for GPI-anchored proteins (8). Caveolae
domains are involved in a variety of physiological and pathological
situations such as signal transduction (9) and entry of nonenveloped
DNA virus SV40, respectively (10, 11). From the plasma membrane,
PrP-sen either can be endocytosed, recycled, and degraded or can bind to PrP-res and thus be converted into newly formed PrP-res aggregates (for review see Ref. 12). The subcellular sites for binding of PrP-sen
to PrP-res and conversion remain unknown. These events could occur
either on the cell surface or into nondefined endocytosis organelles
during PrP-sen trafficking (13, 14). Recently, Baron et al.
(15) have shown that raft-bound PrP-sen can be substrate for conversion
only when PrP-res molecules are themselves inserted into contiguous
membranes. Once PrP-res is formed, it appears to accumulate on the
surface of cells (6) and/or into lysosomes (13). Both sterol-binding
antibiotics amphotericin B and lovastatin, which decrease the
membrane cholesterol level, inhibit the formation of PrP-res in
scrapie-infected N2a cells (16, 17). Likewise, the replacement of the
GPI anchor of PrP by a transmembrane domain targets mutated PrP to
clathrin-coated pits, resulting in the decrease of PrP-res formation
(18). Collectively, these reports strongly support the idea that rafts
could be the sites for conversion and PrP-res accumulation.
The PrP-sen amino terminus contains a series of histidine- and
glycine-rich octapeptide repeats that are copper ion-binding sites
(19). Interestingly, cooper ions stimulate endocytosis of PrP-sen (20),
suggesting that PrP could serve as a chelator for uptake and delivery
of copper ions to intracellular targets. Alternatively, copper ions
could be essential cofactors for some yet unknown physiological
functions of PrP-sen.
Here we have assessed the copper-induced endocytosis of PrP-sen using
two complementary approaches. First, by immunolocalization and confocal
laser microscopy observation, we show that copper stimulates PrP-sen
endocytosis through a caveolin-dependent pathway in both
human microglia and mouse neuroblastoma cells. Second, we demonstrate
that the binding of a radiolabeled PrP-recognizing monoclonal antibody
can be used to assess quantitatively internalization of membrane-bound
PrP-sen. Moreover, we show that the polyene antibiotic filipin that
binds to membrane sterols both inhibits PrP endocytosis and provokes
the release of the PrP molecules from the plasma membrane. As a result,
filipin is found to be a potent inhibitor of PrP-res formation in
scrapie-infected N2a cells.
Reagents and Antibodies--
Proteinase K and Pefabloc® were
purchased from Roche Molecular Biochemicals. Dulbecco's modified
Eagle's medium (DMEM), Opti-MEM, trypsin, and Geneticin G418 were from
Invitrogen, and fetal bovine serum (FBS) was from Biomedia. Fresh
solutions of chlorpromazine, nystatin, and filipin (Sigma) were
prepared every day. Mouse monoclonal antibodies SAF32 and SAF70 were
raised in knock-out mice (21) by immunizing with a scrapie-associated
fibrils (SAF) preparation obtained from infected hamster brain
(263K strain). SAFs were denaturated before immunization by treatment
with formic acid. Monoclonal antibody SAF32 was directed against the
entire octarepeat region, whereas SAF70 recognized the 142-160
sequence (22). Both antibodies cross-react with PrP from most mammalian
species (bovine, ovine, mouse, hamster, and human). Monoclonal
antibodies Pri-308 was raised in Biozzi's mice by immunizing with a
synthetic peptide representative of the human 106-126 sequence (22)
and binds only PrP from human and hamster. Rabbit polyclonal antibody R30 was raised against the synthetic prion peptide 89-103 of the mouse
sequence. The anti-caveolin-1 antibody was from Santa Cruz. Secondary
antibodies conjugated to peroxidase, fluorescein isothiocyanate, or
Texas Red and Alexa 488-transferrin were from Jackson
ImmunoResearch (West Grove, PA).
Cell Culture--
The human microglia cell line C13-NJ, a
generous gift of Dr. Tardieu (Le Kremlin-Bicêtre, France), was
established after transfection of large T antigens and was
cultivated into DMEM supplemented with 10% FBS and
penicillin-streptomycin (23). Neuroblastoma 3F4-N2a cells
overexpressing murine PrP in which residues 108 and 110 were replaced
by methionine were cultivated as described previously (24).
Neuroblastoma N2a cells overexpressing mouse PrP (subclone 58) were
cultivated in Opti-MEM containing 10% inactivated FBS,
penicillin-streptomycin, and 1 mg/l G418. This cell line has been
chronically infected with Chandler strain-infected mouse brain and was
named N2aS12 sc+ (25). Because the treatment of N2aS12
sc+ cells with Congo Red (1 µg/ml) allowed the total cure
of the cells of PrP-res, Congo Red-treated N2aS12 cells were used here as a control. The cells were maintained at 37 °C in 5%
CO2 atmosphere in a biohazard laboratory and were split
every 4 days at a 1:5 ratio.
Confocal Microscopy--
The day before the experiment, C13-NJ,
3F4-N2a, and N2aS12 cell lines were grown on glass coverslips (Lab-Tek)
in DMEM supplemented with 10% FBS. For cell surface PrP-sen detection
experiments, coverslips were washed twice with phosphate-buffered
saline (PBS) and then incubated in DMEM containing 10% FBS in the
absence or in the presence of filipin (5 µg/ml), nystatin (50 µg/ml) for 15 min, or chlorpromazine (5 µg/ml) for 30 min at
37 °C. To stimulate endocytosis of cell surface PrP,
CuSO4 was added to the medium to a final concentration of
500 µM for 30 min. Then the cells were washed three times
with PBS and fixed in paraformaldehyde 3% in PBS for 10 min or 20 min
for the N2aS12 and C13-NJ cell lines, respectively. The cells were
washed twice with PBS and then incubated in PBS containing 50 mM NH4Cl for 10 min to quench excess of free
aldehyde groups. After 20 min in PBS with 10% inactivated horse serum
(HS), each coverslip was incubated for 90 min in PBS with 5% HS
containing appropriate antibodies (Pri308 diluted 1:300; R30 diluted
1:500; SAF70 diluted 1:300; and anti-caveolin-1 diluted 1:500). The
cells were rinsed three times in PBS and then incubated with the
appropriate conjugated secondary antibodies (1/600) in PBS with 5% HS
for 45 min. When indicated, the incubations with secondary antibodies
were done on permeabilized cells, i.e. in PBS with 5% HS
supplemented with 0.1% Triton X-100.
For the endocytosis studies, the PrP-sen was immunodetected by
incubating the cells with the indicated antibodies in PBS containing 1% bovine serum albumin for 90 min at 37 °C. Transferrin receptors or caveolae were detected with 50 µg/ml iron-saturated Alexa
488-transferrin or a 1:300 diluted anti-caveolin-1 antibody,
respectively. The endocytosis of PrP-sen was initiated by incubating
cells with a 500 µM solution of CuSO4 for 30 min at 37 °C. The cells were then washed three times with PBS and
fixed in PBS containing 3% paraformaldehyde for 10 min or 20 min for
the N2aS12 and C13-NJ cell lines, respectively. The coverslips were
washed twice with PBS, quenched with PBS containing 50 mM
NH4Cl, and incubated with the conjugated secondary
antibodies in PBS with 5% HS with 0.1% Triton X-100. After three
washes in PBS and one wash in distilled water, the coverslips were
mounted on glass slides with Mowiol. The cells were observed with a
laser scanning confocal inverted microscope (Leica, TCS-SP) equipped
with an argon-krypton laser. The samples were scanned under both 488- and 568-nm excitation wavelength for fluorescein
isothiocyanate-conjugated secondary antibodies and Alexa
488-transferrin and for Texas Red-conjugated secondary antibodies,
respectively. The images were acquired as single transcellular optical
sections and averaged over at least 8 scans/frame.
Binding Experiments of Radiolabeled Pri308
Antibody--
Purified IgG Pri308 (50 µg) was radioiodinated in the
presence of 0.5 nmol of sodium iodide (125INa 0.1 mCi/µl)
for 10 min at room temperature by IODO-GEN (Pierce) according to the
indirect labeling method as described previously (26). To prevent
unspecific binding of the antibody, 500 µl of bovine serum albumin (2 mg/ml) was added to the reaction medium before purification by
Sephadex-G25 chromatography (Amersham Biosciences). The
radioactivity associated to intact IgGs was quantified by immunoprecipitation using protein G-Sepharose and represented 85-90%
of the total radioactivity. For the cell binding assay, radioiodinated
Pri308 antibody (~800,000 cpm/300 µl; ~3.5 nM) in
Earle's buffer EDTA-free (25 mM Hepes, pH 7.4, 140 mM NaCl, 5 mM KCl, 0.8 mM
MgCl2, 1.8 mM CaCl2, 1 g/liter
glucose, 0.2% bovine serum albumin) was added to confluent C13-NJ
cells plated 48 h before in 24-well tissue culture plates. The
incubations were performed at 37 °C for the indicated times for
kinetics or 90 min for equilibrium studies. At steady state
(i.e. 90 min at 37 °C), the incubation medium was rapidly
removed, and the endocytosis of 125I-Pri308 was stimulated
by incubating cells with 300 µl of Earle's buffer containing 500 µM CuSO4. At the end of the incubation time, the medium was removed, and the cells were rapidly washed twice with 1 ml of Earle's buffer. To estimate the amount of cell-sequestrated 125I-Pri308, the surface-bound radioactivity was removed by
washing cells for 4 min at 37 °C with 500 µl of Earle's buffer
pH4 containing 0.5 M NaCl (acid-NaCl buffer). In control
conditions, the acid wash consistently removed ~95% of the cell
surface radioactivity. Finally, the cells were lysed with 500 µl of
0.2 N NaOH, and the radioactivity was counted in a Assay for Release of PrP-sen from Cells--
Confluent cultures
of C13-NJ or N2aS12 cells plated in 12-well tissue culture plates were
washed four times with PBS containing 1% glucose, 10 µM
bestatine, and a complete mixture of protease inhibitors EDTA-free
(Roche Molecular Biochemicals) prior incubation in the presence or in
the absence of filipin (5 µg/ml) at 37 °C. At the end of the
incubation time, the culture media were collected and trichloroacetic
acid-precipitated. The pellets were resuspended in 50 µl of
denaturing loading buffer (65 mM Tris-HCl, pH 6.8, containing 5% SDS, 3% urea, 5% Assay for PrP-res Accumulation in
N2aS12sc+--
N2aS12sc+ cells were seeded at
10-15% confluent density in a 24-well culture plate in Opti-MEM
supplemented with 10% FBS. Four hours after plating at 37 °C, the
cells were treated with the indicated concentrations of filipin,
nystatin, or chlorpromazine for 4 days. Confluent cultures were lysed
for 10 min at 4 °C in lysis buffer (50 mM Tris-HCl, pH
7.4, containing 150 mM NaCl, 0.5% Triton X-100, 0.5%
sodium deoxycholate, 5 mM EDTA) and then centrifuged for 5 min at 3,000 × g. For detection of PrP-sen, one-tenth
of the post-nuclear supernatants were directly mixed with the same
volume of 2× denaturing loading buffer. For detection of PrP-res, the
samples were digested with 20 µg of proteinase K/mg of total protein
for 30 min at 37 °C. The digestion was stopped by adding Pefabloc®
(1 mM) for 5 min before centrifugation at 20,000 × g for 90 min at room temperature. The pellets were
resuspended in 30 µl of denaturing loading buffer, sonicated, boiled
for 5 min, and loaded onto a 12% polyacrylamide gel. PrP-sen and
partially digested PrP-res were assayed with SAF70 monoclonal antibody
diluted 1:1000 in TBST. The blots were developed and exposed as
described above. Densitometry was performed with National Institutes of Health Image software, computing at least four independent experiments, and the results are expressed as percentages of the control condition.
Copper-induced Subcellular Relocalization of Cell Surface
PrP-sen--
A previous report showed that copper stimulates the
endocytosis of PrP-sen in neuroblastoma cells. Using confocal laser
microscopy, we further investigated the relocalization of cell surface
PrP-sen induced by copper. Human microglia cells were incubated in the absence (Fig. 1A) or in the
presence of 500 µM CuSO4 (Fig. 1B) for 30 min at 37 °C. After paraformaldehyde fixation, the cell surface PrP was assayed by incubation with Pri308 antibody and revealed
by a Texas Red-conjugated secondary antibody under nonpermeabilized conditions (Fig. 1, A and B). Whereas the
fluorescence was found associated to the cell surface of the microglia
cells in control conditions, the copper incubation induced a
significant disappearance of the cell-associated fluorescence (Fig. 1,
A and B), suggesting the existence of a
copper-induced PrP endocytosis mechanism. To further characterize this
mechanism, microglia cells were first incubated with Pri308 for 90 min
at 37 °C to specifically label the surface-bound PrP-sen and then
submitted to copper stimulation. The confocal microscopy observations
were performed on permeabilized cells. Copper-stimulated cells
displayed an intense perinuclear fluorescent pattern, confirming that
copper induced the relocation of PrP-sen from the cell membrane to
intracellular compartments (Fig. 1C). At this point of our
study, we cannot rule out the possibility that PrP-sen trafficking is
disturb by the binding of Pri308. However, several lines of evidence
will be provided later in the manuscript showing that the binding of
Pri308 does not modify the copper-induced internalization of PrP.
Differentiation of Copper-induced PrP-sen Endocytosis through
Coated and Noncoated Pathways--
To further investigate the pathway
of copper-induced PrP-sen internalization, we performed
immunocytochemical colocalization experiments both with anti-PrP
monoclonal antibody and with a specific marker of the
clathrin-dependent endocytosis pathway (transferrin-Alexa
488) and/or anti-caveolin-1 antibody to label the caveolae structures.
As shown in Fig. 2, when endocytosis of
PrP is induced by copper ions, PrP is relocalized into
caveolin-1-positive intracellular compartments in human microglia
cells. Moreover, the superimposed images clearly revealed the absence
of colabeling fluorescence between the anti-PrP antibody and the
transferrin receptor marker in both microglia and neuroblastoma cells.
These results strongly suggest that copper-induced PrP endocytosis
occurred via a caveolae-dependent pathway. Although it is
well established that microglia cells contain caveolae and caveolin
(27), no caveolin labeling was detected in mouse N2a by
immunofluorescence confocal microscopy and Western blotting analysis
(results not shown), in agreement with previous report (28).
Effects of Filipin, Nystatin, and Chlorpromazine on the
Relocalization of PrP-sen Induced by Copper--
In the absence of
marker of the caveolae-dependent endocytosis pathway in
neuroblastoma cells, we examined the effect of two classes of drugs on
PrP-sen endocytosis. Sterol-binding agents such as filipin and nystatin
bind to cholesterol, a major component of glycolipid microdomains and
caveolae, and disrupt caveolar structure and function (27, 29). On the
other hand, chlorpromazine inhibits the clathrin-dependent
pathway (30, 31). Human microglia and 3F4-PrP expressing neuroblastoma
cells were incubated in the absence or in the presence of filipin,
nystatin, or chlorpromazine prior to copper stimulation for 30 min and
paraformaldehyde fixation. The cell surface PrP-sen molecules were
monitored by staining with Pri308 antibody. The observations were
performed by confocal laser microscopy on nonpermeabilized cells. In
control conditions, the cells exhibited a loss of fluorescence at the
plasma membrane after copper stimulation, confirming the endocytosis of
PrP-sen from the surface to the inside of the cell (Fig.
3A). In contrast, fluorescence
was found only at the cell surface of filipin- or nystatin-treated
cells, indicating that these cells were unable to significantly
internalize PrP-sen after copper stimulation. In contrast,
chlorpromazine-treated cells displayed a loss of cell surface
fluorescence similar to that of untreated cells. Thus, the results with
filipin and nystatin indicated that copper-induced PrP endocytosis
occurred through cholesterol-rich microdomains including the possible
involvement of caveolae in both human microglia and neuroblastoma
cells. The interaction of filipin with cholesterol and its inhibitory
effects on the copper-induced PrP-sen endocytosis can be demonstrated
in both caveolin-expressing or caveolin-devoid cells.
Knowing that transferrin receptors are internalized via clathrin-coated
pits, we further compared the distribution of Alexa 488-transferrin
into neuroblastoma cells in control, filipin-treated, and
chlorpromazine-treated cells. As shown in Fig. 3B, control and filipin-treated cells exhibited a largely perinuclear fluorescence pattern with a concomitant loss of plasma membrane labeling. In contrast, Alexa 488-transferrin fluorescence was found predominantly at
the cell surface of chlorpromazine-treated cells, indicating that these
cells did not internalize transferrin receptors. Other fields
from chlorpromazine-treated neuroblastoma cells occasionally showed some internalized Alexa 488-transferrin
fluorescence; however, the pattern was diffuse and remained in the
region underlying the plasma membrane. In summary, we confirmed that
transferrin receptor, a typical clathrin-dependent
endocytosis pathway, was insensitive to filipin and also to nystatin
treatment (data not shown), whereas it could be efficiently inhibited
by chlorpromazine.
Binding of 125I-Pri308 Antibody to Human Microglia
Cells (C13-NJ)--
The goal of these studies was to characterize the
kinetic parameters of PrP-sen internalization induced by copper using
the approach of binding of radiolabeled monoclonal antibody Pri308 to
the cell surface. This antibody was chosen from a panel of antibodies
developed against PrP essentially because Pri308 is able to recognize
the human PrP-sen in native conditions. The binding of the
125I-Pri308 antibody to the cell surface was specific
because the radiolabeled IgG bound can be displaced by 10 µM of synthetic peptide sequence 106-128 or by an excess
of unlabeled Pri308 (Fig. 4) but not by a
100-fold excess of unlabeled nonimmune mouse IgG (data not shown).
Moreover, the binding of 125I-Pri308 on confluent mouse
PrP-overexpressing N2a cells was similar to nonspecific binding (data
not shown). The binding equilibrium of 125I-Pri308 was
reached by 90 min at 37 °C. In subsequent experiments, the cells
were incubated with 125I-Pri308 for 90 min at 37 °C,
then rapidly rinsed, and incubated in the presence or in the absence of
500 µM of CuSO4 for different times. At the
end of the incubation time, the cells were submitted to a hyperosmotic
acid wash for 4 min. In the presence of copper, the acid wash-resistant
binding increased rapidly, reached a plateau (~38% of total binding)
at 30 min, and was stable for at least 60 min. In the absence of
cooper, the acid wash-resistant binding never exceeded 5% of the total
binding (Fig. 4, inset), demonstrating that IgG binding did
not provoke PrP-sen internalization by itself. Using this procedure, we
determined that the concentration of copper able to induce 50% of
maximal internalization was 125 µM (data not shown).
After 30 min at 37 °C, 500 µM ZnSO4,
NiCl2, and CoCl2 also stimulated the
endocytosis of 25I-Pri308 antibody into human microglia
cells by 25, 14, and 10% of the total binding, respectively; no effect
was seen with MnCl2 and FeSO4 (data not
shown).
Effects of Filipin and Chlorpromazine on Binding and Copper-induced
Internalization of 125I-Pri308 Antibody to Human Microglia
Cells--
We next examined the effects of filipin and chlorpromazine
on both the 125I-Pri308 specific binding and the
copper-induced endocytosis assays to human microglia cells. As
expected, the cells treated with filipin exhibited a significant
decrease in the amount of acid wash-resistant binding of
125I-Pri308 antibody after copper stimulation (Fig.
5A, right panel). Surprisingly, the filipin treatment also induced a decrease of the
specific binding of 125I-Pri308 antibody in a
time-dependent manner (Fig. 5A, left
panel). One hour of filipin treatment resulted in a 60% decrease
of the 125I-Pri308-specific binding (Fig. 5A).
The inhibition of the cell surface binding of radiolabeled IgG by
filipin was concentration-dependent (Fig. 5B).
In the course of these experiments, there was no evidence for
cytotoxicity or reduced protein synthesis in human microglia cultures
exposed to filipin. Chlorpromazine had no effect on the 125I-Pri308 antibody-specific binding to C13-NJ cells nor
on copper-induced endocytosis mechanism (Fig. 5A). In
summary, we show that filipin decreases the cell surface-specific
binding of 125I-Pri308 antibody and inhibits the
copper-induced endocytosis of the remaining PrP-sen molecules.
Filipin Induces Release of PrP-sen from Cell Surface of Human
Microglia and Mouse Neuroblastoama Cells--
The decrease in cell
surface-specific binding of 125I-Pri308 antibody induced by
filipin could be due to a release of PrP-sen from the cell surface into
the culture medium. To investigate this possibility, C13-NJ and 3F4-N2a
cells were treated with filipin, and the culture media were assayed for
the presence of PrP-sen by Western blot. As shown in Fig.
6, treatment of both type of cells by
filipin induces the release of fully matured PrP-sen into the medium in
a time-dependent manner. In these experiments, if the
mixture of protease inhibitors was omitted, the amino-terminal epitope
of SAF32 antibody was rapidly destroyed (data not shown), whereas the
epitopes of SAF70 and Pri308 remained intact. In summary, filipin
induces a continuous release of membrane-bound PrP-sen into the
medium.
Inhibition of PrP-res Formation in N2a S12sc+ Cells by
Filipin--
Because filipin treatment results in a release of cell
surface PrP-sen, we asked whether filipin could also inhibit the
PrP-res accumulation in chronically infected N2a S12sc+
cells. N2a S12sc+ cells were incubated continuously for 4 days with various concentrations of filipin, and then cell lysates were
assayed for the presence of proteinase K-resistant isoforms of PrP
(Fig. 7A). Alternatively, discontinuous treatment of cells was performed with filipin for 30 min
twice a day for 4 days (data not shown). In both types of treatment,
filipin reduced the amount of detectable PrP-res in a
dose-dependent manner with an IC50 of 1.25 µg/ml i.e. 2 µM (Fig. 7B). No
cytotoxicity was observed within the range of filipin concentrations
used in these experiments. Moreover, PrP-sen synthesis was not affected
by the filipin treatment (data not shown). As described previously
(32), we observed that chlorpromazine also inhibits PrP-res
accumulation into our N2a S12sc+ cells system (data not
shown).
In the present report, we investigate the mechanism of PrP
endocytosis induced by copper ions in both overexpressing mouse PrP
neuroblastoma and endogenous PrP expressed human microglia cells.
Having quantitatively assayed the surface-bound and the caveolae-mediated trafficking pathway of PrP, we showed that disruption of cholesterol-rich domains could prevent PrP-res accumulation.
PrP trafficking has been previously investigated by indirect procedures
using cell surface iodination or biotinylation (20, 33). In the
radiolabeling IgG binding assay used in this study, several technical
differences should be pointed out. First, the use of monoclonal
antibody Pri308, which recognizes the 106-126 epitope of the human PrP
sequence, allows us to selectively measure the unprocessed PrP
molecules. Indeed, it has been shown that PrP-sen is submitted to a
physiological proteolytic process occurring around amino acid residues
110-111 (34, 35), giving rise to disruption of the Pri308-recognized
epitope. A significant part of PrP-sen molecules present at the surface
of cells are amino terminus-shortened and thus are not taken into
account in our radiolabeled IgG assay. Second, in light of studies
showing that bivalent antibodies can alter the normal endocytotic
pathway of receptor (36, 37), we could not be sure a priori
that this approach accurately reflected PrP trafficking. Several lines
of evidence show that binding of whole IgG to PrP does not induce internalization. In the absence of copper stimulation, no acid wash-resistant (i.e. internalized) 125I-Pri308
was measured in the course of the incubations. Our results were
consistent with those obtained using the cell surface
iodination/biotinylation assay, in terms of endocytosis kinetics,
divalent ions efficiencies, and concentrations of copper required for
induction of PrP endocytosis (20, 33). Moreover, a similar approach has
been successfully used to characterize the trafficking of cell surface
amyloid Previous reports have shown a subcellular localization of surface-bound
PrP-sen in caveolae membranous domains (6, 18). However, other
investigators have reported that endocytosis of chicken PrP-expressing
N2a cells is mediated via clathrin-coated pits (28). These
discrepancies could be due to the high divergence between mammalian and
chicken PrP sequences (~30% homology) and to the considerable
overexpression of exogenous PrP molecules into neuroblastoma cells.
Moreover, authors have well studied unstimulated endocytosis of PrP but
failed to characterize the copper-stimulated endocytosis pathway (20,
28). The possibility that copper-induced endocytosis and unstimulated
turnover of PrP take out different endocytosis pathways cannot be ruled out.
PrP-sen has been shown to bind copper ions in vitro and
in vivo likely via the octarepeats amino-terminal region
encompassing residues 60-91 (19, 39). More recently, Jackson et
al. (40) have accurately characterized two classes of
copper-binding sites within the human PrP sequence. The first one is
located in the amino-terminal octapeptide repeats and specifically
binds copper ions with a Kd value of
10 In our attempts to further characterize the copper-stimulated
endocytosis pathway, we used two classes of drugs described as specific
blockers of caveolae- and clathrin-dependent pathways (47).
Sterol-binding agents such as filipin and nystatin bind to cholesterol,
a major component of glycolipid microdomains and caveolae, and disrupt
caveolae structure and function (27, 29). In contrast, cationic
amphiphilic drugs such as chlorpromazine act on the
clathrin-dependent pathway and inhibit receptor-mediated endocytosis by reducing the number of coated pit-associated receptors at the cell surface (30, 31). In our cell models, filipin efficiently
blocks the copper-stimulated endocytosis of PrP-sen. Moreover, under
copper-induced internalization conditions, PrP-sen labeling never
colocalizes with transferrin, a marker of the
clathrin-dependent pathway, and colocalizes with caveolin.
Taken together, our results strongly suggest that copper-stimulated PrP
endocytosis occurs via lipid rafts in both neuronal and non-neuronal
cells. Surprisingly, filipin also induces the release of fully matured
PrP molecules from the cell surface, likely by interacting with
membrane sterols. Based on its sterol binding properties, we
hypothesize that filipin alters the caveolar structures, resulting in
both inhibition of endocytosis process and release of GPI-anchored PrP
molecules. To our knowledge, this is the first report showing that
filipin is capable of releasing a GPI-anchored protein.
Acute or chronic filipin treatments of scrapie-infected N2a efficiently
inhibit PrP-res accumulation. It was proposed that the PrP-sen/PrP-res
conversion process could be compared with a autocatalytic
polymerization reaction (48) occurring somewhere between the cell
surface and the organelles of the endocytic pathway. Thus, decreasing
the level of PrP-sen substrate leads to an inhibition of PrP-res
formation. Both inhibition of endocytosis of PrP and release of
membrane-bound PrP induced by filipin could produce additional effects
by removing the substrate available for conversion. Note that
phosphatidylinositol-specific phospholipase C treatment inhibits PrP-res formation into infected N2a cells likely by cleavage of the GPI anchor and release of PrP from the cell surface (4). There
is a lot of evidence showing that filipin, amphotericin B, and
nystatin, which belong to the same polyene antibiotic family, interact
with cholesterol (for review see Ref. 49). Although amphotericin B is
one of the most potent anti-scrapie agents, its mechanism of action
remains unclear (16, 50). In our radiolabeled IgG assays, no effect of
amphotericin B was found on PrP endocytosis and on the release of cell
surface PrP, suggesting that its mechanism of action differs from that
of filipin. The same statement has been made concerning chlorpromazine,
which inhibits PrP-res formation in infected N2a
(32)2 remains without effect
on surface-bound PrP relocalization. The anti-scrapie mechanisms of
action of both chlorpromazine and amphotericin B remain to be characterized.
It has been shown that caveolae-like domains isolated from infected N2a
contain PrP-res (6). However, we never detected PrP-res in the culture
medium of infected N2a treated by filipin, suggesting that the
anchorage of PrP-res at the cell surface may be insensitive to
disruption of lipid rafts.
In conclusion, our results further document the crucial role played by
caveolae-like domains in the cellular events leading to PrP-res
formation. The identification of drugs such as filipin that disturb the
trafficking of PrP underscores the role of lipid rafts in the
pathogenesis of TSE and may provide new therapeutic strategies.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
counter (Packard). The protein concentration was assayed by measuring
the ratio of optical densities at 260 nm/280 nm. Nonspecific binding
was determined in the presence of a large excess of unlabeled Pri308
(50 µg/ml; 1 µl/well) or of synthetic human prion peptide 106-128
(10 µM). In both cases, the nonspecific binding
represented less than 8% of the total binding. Specific binding was
calculated by subtracting nonspecific binding from total binding.
-mercaptoethanol, 10%
glycerol, 0.05% bromphenol blue), boiled for 5 min, and loaded onto a
12% polyacrylamide gel. The proteins were separated by SDS-PAGE and then electroblotted onto a nitrocellulose membrane (Protran BA83; Schleicher & Schuell). The membranes were treated with 5% nonfat dry
milk in TBST (20 mM Tris-HCl, pH 8, 100 mM
NaCl, 0.1% Tween 20) and incubated overnight with the appropriate
primary antibody at 4 °C. The blots were developed by using an
enhanced chemoluminescence system (Roche Molecular Biochemicals) and
exposed on x-ray film (X-Omat AR; Eastman Kodak Co.).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (14K):
[in a new window]
Fig. 1.
Copper-induced relocalization of membranous
PrP. A and B, Human microglia cells
C13-NJ were incubated in the presence (B) or in the absence
(A) of 500 µM CuSO4 for 30 min at
37 °C. The cells were rapidly rinsed and fixed with 3%
paraformaldehyde for 20 min. Membrane-bound PrP was detected by
incubating unpermeabilized cells with a 1:300 dilution of Pri 308 and a
Texas Red-conjugated secondary antibody. Identical photomultiplicator
values and parameters of the laser scanning confocal microscope were
used in A and B. C, C13-NJ cells were
incubated with Pri 308 in DMEM 10% FBS for 90 min. At the end of the
incubation, 500 µM CuSO4 was added to the
medium for 30 min at 37 °C. The cells were then rinsed and incubated
for 45 min at 37 °C in DMEM containing 10% FBS. After
paraformaldehyde fixation, Pri308 monoclonal antibody was detected with
a secondary conjugated antibody on permeabilized cells as described
under "Experimental Procedures." Scale bar, 15 µm.

View larger version (17K):
[in a new window]
Fig. 2.
Endocytosed PrP colocalizes with
caveolae-like domains and not with transferrin. Human microglia
and mouse neuroblastoma cells were incubated for 2 h at 37 °C
with Pri308 or R30 antibodies, respectively. Forty minutes before the
end of the incubation time, CuSO4 (500 µM)
and Alexa 488-transferrin (50 µg/ml) were added as indicated. The
cells were then rinsed, fixed, and permeabilized, and the presence of
anti-PrP antibodies was revealed with a Texas Red-conjugated secondary
antibody. Caveolin-1 protein was detected with an anti-caveolin-1
antibody and a fluorescein isothiocyanate-conjugated secondary
antibody. No caveolin-1 labeling could be detected into N2a cells (not
shown). The yellow color indicates the red and green
colabeling. The arrowheads show clusters of colabeling.
Scale bar, 15 µm.

View larger version (47K):
[in a new window]
Fig. 3.
Effects of filipin, nystatin, and
chlorpromazine on the relocalization of cell surface-bound PrP and
transferrin receptors. A, C13-NJ and 3F4-N2a cells were
treated with 5 µg/ml filipin or 50 µg/ml nystatin for 15 min or
with 5 µg/ml chlorpromazine for 30 min at 37 °C. CuSO4
(500 µM) was then added to the incubation medium for 30 min. After a rapid wash with PBS, surface-bound PrP was revealed on
unpermeabilized cells with Pri308 and Texas Red-conjugated secondary
antibody. Identical photomultiplicator values and parameters of the
laser scanning confocal microscope were used for all of the panels.
B, 3F4-N2a cells were preincubated with DMEM containing 1%
bovine serum albumin for 90 min at 37 °C. The cells were then
incubated in the absence (panels a and a') or in
the presence of 5 µg/ml filipin (panels b and
b') or 5 µg/ml chlorpromazine for 30 min (panels
c and c'). The incubation medium was removed, and the
cells were incubated in the presence of a solution of Alexa
488-transferrin for 30 min at 37 °C. The cells were then rinsed,
fixed with 3% paraformaldehyde, and observed with a laser scanning
confocal microscope. Panels a, b, and
c, confocal microscopy images. Panels a',
b', and c', overlay representations of confocal
and transmission microscopy observations.

View larger version (19K):
[in a new window]
Fig. 4.
Association and copper-induced endocytosis
kinetics of 125I-Pri308 antibody to human microglia
cells. Confluent C13-NJ cells plated into 24-well tissue culture
plates were incubated at 37 °C in Earle's buffer containing
125I-Pri308 monoclonal antibody (800 000cpm/300 µl) in
the absence (black circles) or in the presence (open
circles) of a large excess of unlabeled Pri308 or 10 µM synthetic peptide P106-128. At the indicated times,
the cells were rapidly washed twice with 1 ml of Earle's buffer and
lysed with 500 µl of 0.2 N NaOH, and the radioactivity
bound to cells was counted. Inset, C13-NJ cells were
incubated in Earle's buffer containing radiolabeled Pri308 antibody
for 90 min at 37 °C. Then the incubation medium was rapidly removed,
and 300 µl of Earle's buffer was added in the absence (open
squares) or in the presence (black squares) of 500 µM CuSO4. At the indicated times, the cells
were treated with Earle's buffer, pH 4, containing 0.5 M
NaCl for 4 min at 37 °C. The results are expressed as the
percentages of acid wash binding compared with the associated
cell-specific binding. The results are means of six independent
experiments where each point is the average of duplicate
determinations.

View larger version (21K):
[in a new window]
Fig. 5.
Effect of filipin and chlorpromazine on the
surface-bound and internalized 125I-Pri308 antibody.
C13-NJ were incubated at 37 °C in Earle's buffer containing
radiolabeled Pri308 (800,000 cpm/300 µl) for 90min. Filipin or
chlorpromazine (chlorpro) were added to the incubation
medium 5, 15, and 30 min prior the end of the radiolabeled IgG
incubation time at a final concentration of 5 µg/ml. The medium was
then removed and replaced by 500 µl of Earle's buffer containing 500 µM CuSO4 and 5 µg/ml of filipin or
chlorpromazine as indicated for an additional incubation time of 30 min
at 37 °C. Finally, the cells were treated with Earle's buffer, pH
4, containing 0.5 M NaCl for 4 min at 37 °C (gray
histograms) or by two washes with 1 ml of Earle's buffer (white
histograms). The radioactivity was recovered by scraping the cells with
500 µl of 0.2 N NaOH and counted. A,
representation of the effects of drugs on cell-associated radiolabeled
Pri308 binding as a function of time. The results are expressed as
percentages of specific binding (i.e. total binding
nonspecific binding) of the control experiment performed in the absence
of drug (left panel). For endocytosis experiments
(right panel), the results are expressed as follows: acid
wash-resistant binding × 100/cell-associated specific binding.
B, dose-response of filipin on the radiolabeled IgG binding.
The results are the means of five independent experiments where each
point is the average of duplicate determinations.

View larger version (53K):
[in a new window]
Fig. 6.
Kinetics of release of surface-bound PrP
induced by filipin treatment. Shown is a representative experiment
performed by treating C13-NJ or N2aS12 cells in the absence (control)
or in the presence of 5 µg/ml of filipin at 37 °C in PBS
containing 1% glucose and a mixture of inhibitors. At the indicated
times, the incubation medium was collected and trichloroacetic
acid-precipitated. The pellets were resuspended in denaturating loading
buffer and analyzed by Western blot. PrP was revealed with the
indicated anti-PrP antibodies and developed with the enhanced
chemoluminescence system. MW, molecular mass.

View larger version (44K):
[in a new window]
Fig. 7.
Effect of filipin on the accumulation of
PrP-res in infected N2aS12. A, immunoblot of a
representative experiment performed by treating cells in the absence
(0) or in the presence of the indicated concentrations of filipin for 4 days. PrP-res was detected with the monoclonal antibody SAF70.
B, dose-response curve of the inhibition of PrP-res
accumulation induced by filipin. The data represent the means of four
independent experiments ± S.D. (bars) and were
expressed as relative quantities of PrP-res in the presence of the drug
compared with the control culture. MW, molecular
mass.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-protein precursor (38). Together, these observations
strongly suggested that the binding of Pri308/PrP does not modify the
copper-induced endocytosis of PrP. In the future, this direct approach
could be a convenient way to determine whether the identified mutations within PrP in human hereditary TSE affect PrP trafficking.
14 M. The second copper-binding site is
included in the carboxyl-terminal domain of PrP and interacts with
various divalent metals with a micromolar affinity. Thus, it is likely
that PrP endocytosis induced by copper, nickel, zinc, and cobalt in the
micromolar range is mediated by the low affinity metal ion-binding
sites. At variance with this line of reasoning, deletion of the
amino-terminal region of PrP (
25-91) including the octapeptide
repeats has been claimed to lead to the abolishment of copper-induction
PrP endocytosis (20, 41). The minimal concentration of copper released
from synaptosomes into the extracellular space upon depolarization conditions has been estimated to be 100 µM (42, 43).
Thus, the physiological relevance of the low affinity metal ion-binding sites of PrP is plausible. However, the existence of natural ligands not yet identified capable of interacting with PrP with a high affinity
and inducing its internalization cannot be ruled out. Interestingly,
direct interactions between PrP and cellular glycosaminoglycans have
been reported (44, 45) as well as the induction of PrP endocytosis by
sulfated glycans (46).
| |
ACKNOWLEDGEMENTS |
|---|
We are grateful to Dr. Caughey and Dr. Schätzl for providing the rabbit polyclonal antibody R30 and the neuroblastoma 3F4PrP-expressing cells, respectively. Very special thanks are due to Pr. Jean-Pierre Vincent for critical reading of the manuscript, Peggy Richard and Roxane Pichot for technical assistance, and Stephane Martin for confocal microscopy advice.
| |
FOOTNOTES |
|---|
* This work was supported in part by French government grants from the "Action Concertée Incitive" Jeunes Chercheurs (2000) and by the "Groupement d'Intèrêt Scientifique" Infections à Prions (2001).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: IPMC, CNRS, 660 Route des Lucioles, 06560 Valbonne, France. Tel.:
334-93-95-77-67; Fax: 334-93-95-77-08; E-mail:
chabry@ipmc.cnrs.fr.
Published, JBC Papers in Press, May 6, 2002, DOI 10.1074/jbc.M203248200
2 M. Marella and J. Chabry, unpublished data.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: TSE, transmissible spongiform encephalopathy(ies); GPI, glycosylphosphatidylinositol; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; SAF, scrapie-associated fibrils; PBS, phosphate-buffered saline; HS, horse serum.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Hope, J., Morton, L. J. D., Farquhar, C. F., Multhaup, G., Beyreuther, K., and Kimberlin, R. H. (1986) EMBO J. 5, 2591-2597[Medline] [Order article via Infotrieve] |
| 2. |
Pan, K.-M.,
Baldwin, M.,
Nguyen, J.,
Gasset, M.,
Serban, A.,
Groth, D.,
Mehlhorn, I.,
Huang, Z.,
Fletterick, R. J.,
Cohen, F. E.,
and Prusiner, S. B.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
10962-10966 |
| 3. | Oesch, B., Westaway, D., Walchli, M., Mckinley, M. P., Kent, S. B., Aebersold, R., Barry, R. A., Tempst, P., Teplow, D. B., Hood, L. E., Prusiner, S. B., and Weissmann, C. (1985) Cell 40, 735-746[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
Caughey, B.,
and Raymond, G. J.
(1991)
J. Biol. Chem.
266,
18217-18223 |
| 5. | Stahl, N., Baldwin, M. A., Teplow, D. B., Hood, L., Gibson, B. W., Burlingame, A. L., and Prusiner, S. B. (1993) Biochemistry 32, 1991-2002[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Vey, M.,
Pilkuhn, S.,
Wille, H.,
Nixon, R.,
DeArmond, S. J.,
Smart, E. J.,
Anderson, R. G.,
Taraboulos, A.,
and Prusiner, S. B.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
14945-14949 |
| 7. | Madore, N., Smith, K. L., Graham, C. H., Jen, A., Brady, K., Hall, S., and Morris, R. (1999) EMBO J. 18, 6917-6926[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Brown, D. A., and Rose, J. K. (1992) Cell 68, 533-544[CrossRef][Medline] [Order article via Infotrieve] |
| 9. |
Sargiacomo, M.,
Sudol, M.,
Tang, Z.,
and Lisanti, M. P.
(1993)
J. Cell Biol.
122,
789-807 |
| 10. |
Kartenbeck, J.,
Stukenbrok, H.,
and Helenius, A.
(1989)
J. Cell Biol.
109,
2721-2729 |
| 11. | Anderson, H. A., Chen, Y., and Norkin, L. C. (1996) Mol. Biol. Cell 7, 1825-1834[Abstract] |
| 12. | Lehmann, S., Milhavet, O., and Mange, A. (1999) Biomed. Pharmacother. 53, 39-46[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Caughey, B.,
Raymond, G. J.,
Ernst, D.,
and Race, R. E.
(1991)
J. Virol.
65,
6597-6603 |
| 14. |
Borchelt, D. R.,
Taraboulos, A.,
and Prusiner, S. B.
(1992)
J. Biol. Chem.
267,
16188-16199 |
| 15. | Baron, G. S., Wehrly, K., Dorward, D. W., Chesebro, B., and Caughey, B. (2002) EMBO J. 21, 1031-1040[CrossRef][Medline] [Order article via Infotrieve] |
| 16. |
Mange, A.,
Nishida, N.,
Milhavet, O.,
McMahon, H. E.,
Casanova, D.,
and Lehmann, S.
(2000)
J. Virol.
74,
3135-3140 |
| 17. |
Taraboulos, A.,
Scott, M.,
Semenov, A.,
Avraham, D.,
Laszlo, L.,
and Prusiner, S. B.
(1995)
J. Cell Biol.
129,
121-132 |
| 18. |
Kaneko, K.,
Vey, M.,
Scott, M.,
Pilkuhn, S.,
Cohen, F. E.,
and Prusiner, S. B.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
2333-2338 |
| 19. | Brown, D. R., Qin, K., Herms, J. W., Madlung, A., Manson, J., Strome, R., Fraser, P. E., Kruck, T., von Bohlen, A., Schulz-Schaeffer, W., Giese, A., Westaway, D., and Kretzschmar, H. (1997) Nature 390, 684-687[Medline] [Order article via Infotrieve] |
| 20. |
Pauly, P. C.,
and Harris, D. A.
(1998)
J. Biol. Chem.
273,
33107-33110 |
| 21. | Manson, J. C., Clarke, A. R., Hooper, M. L., Aitchison, L., Mcconnell, I., and Hope, J. (1994) Mol. Neurobiol. 8, 121-127[Medline] [Order article via Infotrieve] |
| 22. | Demart, S., Fournier, J. G., Creminon, C., Frobert, Y., Lamoury, F., Marce, D., Lasmezas, C., Dormont, D., Grassi, J., and Deslys, J. P. (1999) Biochem. Biophys. Res. Commun. 265, 652-657[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Janabi, N., Peudenier, S., Heron, B., Ng, K. H., and Tardieu, M. (1995) Neurosci. Lett. 195, 105-108[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Gilch, S., Winklhofer, K. F., Groschup, M. H., Nunziante, M., Lucassen, R., Spielhaupter, C., Muranyi, W., Riesner, D., Tatzelt, J., and Schätzl, H. M. (2001) EMBO J. 20, 3957-3966[CrossRef][Medline] [Order article via Infotrieve] |
| 25. |
Nishida, N.,
Harris, D. A.,
Vilette, D.,
Laude, H.,
Frobert, Y.,
Grassi, J.,
Casanova, D.,
Milhavet, O.,
and Lehmann, S.
(2000)
J. Virol.
74,
320-325 |
| 26. |
Riske, F.,
Hakimi, J.,
Mallamaci, M.,
Griffin, M.,
Pilson, B.,
Tobkes, N.,
Lin, P.,
Danho, W.,
Kochan, J.,
and Chizzonite, R.
(1991)
J. Biol. Chem.
266,
11245-11251 |
| 27. | Rothberg, K. G., Heuser, J. E., Donzell, W. C., Ying, Y. S., Glenney, J. R., and Anderson, R. G. (1992) Cell 68, 673-682[CrossRef][Medline] [Order article via Infotrieve] |
| 28. |
Shyng, S. L.,
Heuser, J. E.,
and Harris, D. A.
(1994)
J. Cell Biol.
125,
1239-1250 |
| 29. |
Rothberg, K. G.,
Ying, Y. S.,
Kamen, B. A.,
and Anderson, R. G.
(1990)
J. Cell Biol.
111,
2931-2938 |
| 30. |
Wang, L. H.,
Rothberg, K. G.,
and Anderson, R. G.
(1993)
J. Cell Biol.
123,
1107-1117 |
| 31. |
Sofer, A.,
and Futerman, A. H.
(1995)
J. Biol. Chem.
270,
12117-12122 |
| 32. |
Korth, C.,
May, B. C.,
Cohen, F. E.,
and Prusiner, S. B.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
9836-9841 |
| 33. |
Shyng, S. L.,
Huber, M. T.,
and Harris, D. A.
(1993)
J. Biol. Chem.
268,
15922-15928 |
| 34. |
Chen, S. G.,
Teplow, D. B.,
Parchi, P.,
Teller, J. K.,
Gambetti, P.,
and Autilio-Gambetti, L.
(1995)
J. Biol. Chem.
270,
19173-19180 |
| 35. |
Vincent, B.,
Paitel, E.,
Frobert, Y.,
Lehmann, S.,
Grassi, J.,
and Checler, F.
(2000)
J. Biol. Chem.
275,
35612-35616 |
| 36. |
Anderson, R. G.,
Brown, M. S.,
Beisiegel, U.,
and Goldstein, J. L.
(1982)
J. Cell Biol.
93,
523-531 |
| 37. |
Ukkonen, P.,
Lewis, V.,
Marsh, M.,
Helenius, A.,
and Mellman, I.
(1986)
J. Exp. Med.
163,
952-971 |
| 38. | Koo, E. H., Squazzo, S. L., Selkoe, D. J., and Koo, C. H. (1996) J. Cell Sci. 109, 991-998[Abstract] |
| 39. | Stockel, J., Safar, J., Wallace, A. C., Cohen, F. E., and Prusiner, S. B. (1998) Biochemistry 37, 7185-7193[CrossRef][Medline] [Order article via Infotrieve] |
| 40. |
Jackson, G. S.,
Murray, I.,
Hosszu, L. L.,
Gibbs, N.,
Waltho, J. P.,
Clarke, A. R.,
and Collinge, J.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
8531-8535 |
| 41. | Sumudhu, W., Perera, S., and Hooper, N. M. (2001) Curr. Biol. 11, 519-523[CrossRef][Medline] [Order article via Infotrieve] |
| 42. | Kardos, J., Kovacs, I., Hajos, F., Kalman, M., and Simonyi, M. (1989) Neurosci. Lett. 103, 139-144[CrossRef][Medline] [Order article via Infotrieve] |
| 43. | Brown, D. R. (2001) Trends Neurosci. 24, 85-90[CrossRef][Medline] [Order article via Infotrieve] |
| 44. | Priola, S. A., and Caughey, B. (1994) Mol. Neurobiol. 8, 113-120[Medline] [Order article via Infotrieve] |
| 45. |
Caughey, B.,
Brown, K.,
Raymond, G. J.,
Katzenstein, G. E.,
and Thresher, W.
(1994)
J. Virol.
68,
2135-2141 |
| 46. |
Shyng, S.-L.,
Lehmann, S.,
Moulder, K. L.,
and Harris, D. A.
(1995)
J. Biol. Chem.
270,
30221-30229 |
| 47. |
Orlandi, P. A.,
and Fishman, P. H.
(1998)
J. Cell Biol.
141,
905-915 |
| 48. | Lansbury, P. T., Jr., and Caughey, B. (1996) Curr. Biol. 6, 914-916[CrossRef][Medline] [Order article via Infotrieve] |
| 49. | Holz, R. W. (1974) Ann. N. Y. Acad. Sci. 235, 469-479[CrossRef][Medline] [Order article via Infotrieve] |
| 50. | Demaimay, R., Adjou, K. T., Beringue, V., Demart, S., Lasmezas, C. I., Deslys, J. P., Seman, M., and Dormont, D. (1997) J. Virol. 71, 9685-9689[Abstract] |
This article has been cited by other articles:
![]() |
R. Kumar, D. McClain, R. Young, and G. A. Carlson Cholesterol transporter ATP-binding cassette A1 (ABCA1) is elevated in prion disease and affects PrPC and PrPSc concentrations in cultured cells J. Gen. Virol., June 1, 2008; 89(6): 1525 - 1532. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Linden, V. R. Martins, M. A. M. Prado, M. Cammarota, I. Izquierdo, and R. R. Brentani Physiology of the Prion Protein Physiol Rev, April 1, 2008; 88(2): 673 - 728. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Campana, A. Caputo, D. Sarnataro, S. Paladino, S. Tivodar, and C. Zurzolo Characterization of the Properties and Trafficking of an Anchorless Form of the Prion Protein J. Biol. Chem., August 3, 2007; 282(31): 22747 - 22756. [Abstract] [Full Text] [PDF] |
||||